<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803231</url>
  </required_header>
  <id_info>
    <org_study_id>12401</org_study_id>
    <secondary_id>F1K-FR-B009</secondary_id>
    <nct_id>NCT00803231</nct_id>
  </id_info>
  <brief_title>Follow-up Data of Patients Treated With XIGRIS® in France</brief_title>
  <official_title>Follow-up Data of Patients Treated With XIGRIS® DROTRECOGIN ALFA (ACTIVATED) in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The transparency commission wishes that the laboratory Lilly France sets up a follow-up study
      describing the conditions of use of Xigris® in France.

      The purpose of this study is to describe the characteristics of the treated patients, the
      conditions of drug use, in particular the conditions of treatment initiation and the clinical
      development of the patients during normal clinical practice, in particular rate and cause of
      mortality within one month.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study as defined by the specific requirements of Transparency
      Commission are as follows:

        -  To describe the characteristics of the patients treated with Xigris®

             -  socio-demographic characteristics,

             -  clinical profile

        -  To determine the conditions of use of Xigris®

             -  To describe previous treatments,

             -  To observe delay before Xigris® initiation,

             -  To describe dose, duration of treatment,

             -  To study the concomitant treatments and the associated treatments

        -  To describe the clinical evolution of the patients

             -  To observe mortality after 1 month

             -  To describe reasons of death
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 and 31 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severe bleeding events</measure>
    <time_frame>28 and 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>28 and 31 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1004</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Retrospective cohort</arm_group_label>
    <description>Patient treated with Xigris between January 2006 and November 2008.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <description>Patient treated with Xigris between November 2008 and November 2009.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients treated with Xigris® between January 1st, 2006 and August 31st 2008 in
        intensive care units in France will be enrolled retrospectively, whereas all adult patients
        treated with Xigris® between September 1st, 2008 and September 1st, 2009 will be enrolled
        prospectively.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients are eligible to be included in the study if they meet the following criteria

          -  Patients treated with Xigris® during the study period in intensive care units in
             France

          -  Patients with a minimum age of 18 years

          -  Patients who are presenting in the normal course of care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon- fri 9AM-5PM eastern time (UTC/GMT- 5 hours,EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this study, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>February 1, 2010</last_update_submitted>
  <last_update_submitted_qc>February 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drotrecogin alfa activated</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

